China Regenerative Medicine International (HKSE:08158) Piotroski F-Score: 7 (As of Aug. 08, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08158 China Regenerative Medicine International Ltd HKSE:08158
30 GF Score
Price HK$0.23
GF Value HK$0.63
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is China Regenerative Medicine International Piotroski F-Score?

China Regenerative Medicine International HKSE:08158 30 Piotroski F-Score is 7 as of Aug. 08, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates HKSE:08158 with a GF Score™ of 30/100 and a GF Value™ of HK$0.63 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,324 Biotechnology companies, China Regenerative Medicine International ranks better than 96.6% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Regenerative Medicine International has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for China Regenerative Medicine International's Piotroski F-Score or its related term are showing as below:

HKSE:08158' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of China Regenerative Medicine International was 7. The lowest was 3. And the median was 4.

China Regenerative Medicine International  (HKSE:08158) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


China Regenerative Medicine International Piotroski F-Score Related Terms


China Regenerative Medicine International Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for China Regenerative Medicine International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Regenerative Medicine International Piotroski F-Score Chart

China Regenerative Medicine International Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 3.00 6.00 7.00

China Regenerative Medicine International Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 0.00 6.00 0.00 7.00

HKSE:08158 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison

For the Biotechnology subindustry, China Regenerative Medicine International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Regenerative Medicine International Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Piotroski F-Score falls into.


HKSE:08158
30GF Score
China Regenerative Medicine International Ltd HKSE:08158
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was HK$27.53 Mil.
Cash Flow from Operations was HK$4.10 Mil.
Revenue was HK$72.06 Mil.
Gross Profit was HK$41.92 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (135.709 + 168.059) / 2 = HK$151.884 Mil.
Total Assets at the begining of this year (Dec24) was HK$135.71 Mil.
Long-Term Debt & Capital Lease Obligation was HK$39.21 Mil.
Total Current Assets was HK$86.04 Mil.
Total Current Liabilities was HK$75.23 Mil.
Net Income was HK$17.75 Mil.

Revenue was HK$90.62 Mil.
Gross Profit was HK$57.65 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (185.897 + 135.709) / 2 = HK$160.803 Mil.
Total Assets at the begining of last year (Dec23) was HK$185.90 Mil.
Long-Term Debt & Capital Lease Obligation was HK$45.47 Mil.
Total Current Assets was HK$58.31 Mil.
Total Current Liabilities was HK$58.87 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Regenerative Medicine International's current Net Income (TTM) was 27.53. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Regenerative Medicine International's current Cash Flow from Operations (TTM) was 4.10. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=27.525/135.709
=0.20282369

ROA (Last Year)=Net Income/Total Assets (Dec23)
=17.752/185.897
=0.09549374

China Regenerative Medicine International's return on assets of this year was 0.20282369. China Regenerative Medicine International's return on assets of last year was 0.09549374. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

China Regenerative Medicine International's current Net Income (TTM) was 27.53. China Regenerative Medicine International's current Cash Flow from Operations (TTM) was 4.10. ==> 4.10 <= 27.53 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=39.213/151.884
=0.25817729

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=45.473/160.803
=0.28278701

China Regenerative Medicine International's gearing of this year was 0.25817729. China Regenerative Medicine International's gearing of last year was 0.28278701. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=86.037/75.225
=1.14372881

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=58.312/58.869
=0.99053831

China Regenerative Medicine International's current ratio of this year was 1.14372881. China Regenerative Medicine International's current ratio of last year was 0.99053831. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

China Regenerative Medicine International's number of shares in issue this year was 304.252. China Regenerative Medicine International's number of shares in issue last year was 304.252. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=41.916/72.055
=0.5817223

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=57.654/90.617
=0.63623823

China Regenerative Medicine International's gross margin of this year was 0.5817223. China Regenerative Medicine International's gross margin of last year was 0.63623823. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=72.055/135.709
=0.53095226

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=90.617/185.897
=0.48745811

China Regenerative Medicine International's asset turnover of this year was 0.53095226. China Regenerative Medicine International's asset turnover of last year was 0.48745811. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Regenerative Medicine International has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
China Regenerative Medicine International (HKSE:08158) has a Piotroski F-Score of 7 as of Aug. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Regenerative Medicine International and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, China Regenerative Medicine International's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, China Regenerative Medicine International ranks #45 out of 1324 companies in the Biotechnology industry, placing it in the top 3.4%.
Is China Regenerative Medicine International's Piotroski F-Score too high?
China Regenerative Medicine International's current Piotroski F-Score of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. China Regenerative Medicine International's value of 7 is 133.3% above this industry median. Based on the distribution chart, China Regenerative Medicine International ranks #45 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #45 out of 1324 companies for Piotroski F-Score. This places China Regenerative Medicine International in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. China Regenerative Medicine International's value of 7 is 133.3% above this benchmark. Historically, China Regenerative Medicine International's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, China Regenerative Medicine International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,324 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Regenerative Medicine International's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current Piotroski F-Score is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Piotroski F-Score is 7, which is 75% above median its 10-year median of 4.00 and 133.3% above the Biotechnology industry median of 3.00. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Piotroski F-Score is 7 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?

Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued. The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63. GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.

Key valuation signals for HKSE:08158:

  • Piotroski F-Score: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
  • GF Score™: 30/100 with 5 warning signs
  • Industry Position: 133.3% above the Biotechnology median (#45 of 1324)

No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Regenerative Medicine International Business Description

Address 132 Nathan Road, Suite 2310-2318, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score

Get the complete analysis for HKSE:08158

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.23
Price
HK$0.63
GF Value